Immuron Ltd represents a commitment to developing novel immunotherapy solutions for infectious and inflammatory diseases. With a focus on gut health, the company aims to address unmet medical needs through its unique oral immunotherapeutic platform. Immuron actively engages in research and clinical trials to provide safe and effective treatments for conditions caused by microbial imbalances. By harnessing the power of the immune system, Immuron seeks to improve people's lives and contribute to advances in healthcare. The company's dedication to innovation and patient well-being underpins its corporate philosophy, driving its mission to revolutionize the field of immunotherapy.

Immuron Ltd is primarily present in Australia and the United States.

Immuron Ltd, a leading biopharmaceutical company, has achieved several significant milestones. Firstly, the company successfully completed a phase 2 clinical trial for its flagship product, IMM-124E, which demonstrated promising results in treating nonalcoholic steatohepatitis (NASH). Secondly, Immuron successfully obtained patents for its IMM-529 product, which aids in preventing travelers' diarrhea and helps military personnel. Moreover, the company expanded its market presence through strategic collaborations with top-tier organizations. Immuron also received regulatory approvals, such as from the FDA and TGA, further validating the effectiveness and safety of its products. These milestones highlight Immuron Ltd's commitment to innovation and its mission to improve global healthcare.

Immuron Ltd, headquartered in Melbourne, Australia, is a biopharmaceutical company specializing in the development and commercialization of oral immunotherapeutics for the treatment and prevention of a range of gut-mediated diseases. Established in 1994, Immuron has a rich history of research and development in the field of immunotherapy. The company focuses on utilizing its proprietary technology platforms to create safe and effective treatments targeting gut-related disorders. With a strong commitment to innovation, Immuron has successfully brought multiple products to market and continues to advance its pipeline. Through strategic partnerships and collaborations, Immuron aims to expand its global presence and improve patient outcomes worldwide.

The main competitors of Immuron Ltd in the market include pharmaceutical companies such as Merck & Co., Inc., Pfizer Inc., and GlaxoSmithKline plc. These companies also focus on the development and commercialization of innovative medical treatments and therapies. Immuron Ltd faces competition in the biopharmaceutical sector, where companies strive to deliver groundbreaking products and solutions. It is essential for Immuron Ltd to leverage its unique technology, research capabilities, and collaborations to stay competitive and ensure its continued success in the market.

Immuron Ltd is primarily active in the biotechnology and pharmaceutical industries.

The business model of Immuron Ltd revolves around developing and commercializing oral immunotherapy products for the treatment of various gut-mediated diseases. The company utilizes its proprietary technology platform to develop and manufacture these therapeutic products, which aim to restore and maintain a healthy balance of gut microflora. Through targeted research and clinical studies, Immuron aims to address unmet medical needs in areas such as diarrhea-predominant irritable bowel syndrome, nonalcoholic steatohepatitis, and liver diseases. By harnessing the potential of its therapeutic candidates, Immuron Ltd strives to improve the health and well-being of patients worldwide.

Det Immuron P/E-forhold er -3,29.

Immuron KUV er 4,65.

AlleAktien Kvalitetsscore for Immuron er 5/10.

Den Immuron omsætning er 4,90 mio. AUD.

Den Immuron indtjening er -6,94 mio. AUD.

Immuron Ltd is an Australian-based biopharmaceutical company mainly engaged in the research and development of orally administered immunotherapies. The company focuses on combating life-threatening bacterial infections and immune system dysfunctions. Immuron's main business area is the development of IMM-124E, a medical product used for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. IMM-124E is a combination of milk antibodies and other active compounds aimed at reducing inflammation, liver cell damage, and fat accumulation in the liver. Immuron is also involved in the development of IMM-529, an orally administered product used for the prevention and treatment of traveler's diarrhea. It contains polyclonal antibodies produced against diarrhea-causing bacteria. The company has also started developing ImmunoN'hancer, another product that can be used for immunosuppression related to inflammatory bowel diseases and immunotherapy for various types of cancer. Immuron is also expanding into the field of animal health, offering a wide range of products including Oralzyme, a supplement to support dental and oral health in dogs and cats, and Travelan, used to prevent traveler's diarrhea in dogs and cats. In conclusion, Immuron is a leading player in immunotherapy and aims to improve patients' lives through its advanced products, innovative research, and strategic partnerships. The company is committed to sustainable development and strives to create products that are beneficial for both patient health and the environment.

Immuron udbetaler et udbytte på 0 AUD fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for Immuron, eller selskabet udbetaler ikke udbytte.

ISIN'en for Immuron er AU000000IMC7.

WKN for Immuron er A0RDPK.

Tickeren for Immuron er IMC.AX.

I løbet af de sidste 12 måneder betalte Immuron en dividende på . Dette svarer til et dividendeudbytte på omkring . For de kommende 12 måneder vil Immuron sandsynligvis betale en dividende på 0 AUD.

Udbytteafkastet for Immuron er i øjeblikket .

Immuron betaler kvartalsvis udbytte. Dette uddeles i månederne .

Immuron betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 AUD. Dette svarer til et dividendeafkast på 0 %.

Immuron bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på Immuron fra den 4.10.2024 på 0 AUD, skulle du have haft aktien i din portefølje før ex-datoen den 4.10.2024.

Udbetalingen af det sidste udbytte blev foretaget den 4.10.2024.

I løbet af 2023 udbetalte Immuron 0 AUD i form af dividender.

Udbytterne fra Immuron udbetales i AUD.